liver toxicity

pause button on blue background
Biotech

UniQure halts mid- to high-dosing for AAV gene therapy

Two patients receiving uniQure’s gene therapy at a mid-level dose have experienced asymptomatic Grade 3 liver enzyme elevations.
Stop sign

FDA puts Intellia CRISPR trials on hold over raised liver enzyme

Oct 30, 2025 6:37am
pause button on blue background

Intellia pauses phase 3 CRISPR trials after patient hospitalized

Oct 27, 2025 9:45am
liver

FDA lifts diabetes hold after Biomea mitigates liver tox risk

Sep 27, 2024 7:10am
tango dancers dancing

Tango drops USP1 inhibitor over liver toxicity in phase 1 trial

May 23, 2024 8:11am
image of a chain with a padclock keeping a gate closed

Rapt faces clinical hold after liver failure in immunology trial

Feb 20, 2024 10:42am